Andere Sprachen Prime Medicine, Inc.

Aktien

A3DW68

US74168J1016

PRME

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 29.04.2024			% 5 Tage	% 1. Jan.
4.86 ^USD	+9.83%		+1.67%	-45.15%

29.04.	Prime Medicine-Aktien steigen, nachdem die FDA den Antrag zur Behandlung der chronischen Granulomatose genehmigt hat	MT
29.04.	Prime Medicine gibt bekannt, dass die FDA den Antrag auf ein neues Prüfpräparat (IND) für PM359 zur Behandlung der chronischen granulomatösen Erkrankung (CGD) genehmigt hat	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance	29.04.
Prime Medicine Gets FDA Clearance for PM359 IND Application	29.04.
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)	29.04.
Prime Medicine Announces FDA Clearance of Investigational New Drug Application for PM359 for the Treatment of Chronic Granulomatous Disease	29.04.
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings	23.04.
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings	23.04.
Prime medicine reports full year 2023 financial results and provides business updates	04.03.
Prime Medicine 2023 Net Loss Narrows	01.03.
Prime Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.03.
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates	01.03.
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates	01.03.
Prime Medicine to Participate in Upcoming Investor Conferences	28.02.
Prime Medicine to Participate in Upcoming Investor Conferences	28.02.
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares	20.02.
Prime Medicine Prices $140 Million Upsized Offering	15.02.
Prime Medicine Announces Pricing of Upsized Public Offering	15.02.
Prime Medicine Announces Proposed Public Offering of Common Stock	14.02.
Prime Medicine Announces Proposed Public Offering of Common Stock	14.02.
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01.02.
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Prime Medicine, Inc.

Aktien

A3DW68

US74168J1016

PRME

Andere Sprachen

Filter